---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-031468"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2026-09-29T20:19:02+00:00"
generated_at: "2026-10-12T13:50:10.117807+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical reports Renuvion study showing 30% elastin increase and 34% inflammation reduction at Day 180

## Summary
- Study published in Plastic and Reconstructive Surgery — Global Open evaluated Renuvion helium plasma RF on skin quality; n=6 completed Day 180.
- Treated tissue showed 30% increase in elastin fiber density and 55% increase in elastin staining intensity vs control.
- Treated tissue had 34% reduction in inflammation and 27% increase in elastin expression incidence vs untreated control.
- 100% of participants reported improvement, satisfaction, and would recommend; 100% showed physician- and patient-assessed aesthetic improvement.
- CEO Charlie Goodwin said findings support Renuvion's biological basis and that Renuvion should be part of every liposuction procedure.

## SEC filing metadata
- accession: 0001437749-26-031468
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2026-09-29T20:19:02+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000143774926031468/0001437749-26-031468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000143774926031468/apyx20260929_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-031468
- JSON: https://secwatch.observer/filing/0001437749-26-031468.json
- Plain text: https://secwatch.observer/filing/0001437749-26-031468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.